Approval date: April 1, 1999

FREEDOM OF INFORMATION SUMMARY

Supplemental New Animal Drug Application NADA 040-209

ROFENAID[®] 40 (sulfadimethoxine and ormetoprim Type A medicated article)

"...for the prevention of coccidiosis caused by *Eimeria kofoidi* and *E. legionensis* in chukar partridges."

Sponsored by:

ROCHE VITAMNS, INC.

I. GENERAL INFORMATION

NADA Number:	040-209
Sponsor:	Roche Vitamins, Inc. 45 Waterview Boulevard Parsippany, New Jersey 07054
Accepted Name:	sulfadimethoxine and ormetoprim Type A medicated article
Trade Name:	ROFENAID [®] 40
Marketing Status:	This is an over-the-counter (OTC) medicated premix.
Supplemental Effect:	Provides for the use of this sulfadimethoxine and ormetoprim medicated premix for the prevention of coccidiosis (<i>Eimeria kofoidi</i> and <i>E. legionensis</i>) in chukar partridges.
	<i>Minor Species Classification</i> : Chukar partridges are classified as minor species. Therefore, this supplement addresses minor species requirements with respect to effectiveness and target animal safety data collection.

II. INDICATIONS FOR USE IN CHUKAR PARTRIDGE

ROFENAID[®] 40 (sulfadimethoxine and ormetoprim) Type A medicated article is indicated for the prevention of coccidiosis caused by *Eimeria kofoidi* and *E. legionensis* in chukar partridges.

III. PRODUCT INFORMATION

- A. Dosage Form: ROFENAID[®] 40 Type A medicated article is available in 50 lb bags. A pound of ROFENAID[®] 40 is added to one ton of feed to obtain 0.02% (0.0125% sulfadimethoxine and 0.0075% ormetoprim) concentration in feeds.
- B. Route of Administration: Orally via feed
- C. Recommended Dosage: Feed continuously to young birds up to 8 weeks of age as a sole ration at the rate of 113.5 g/ton (0.0125%) of sulfadimethoxine and 68.1 g/ton (0.0075%) of ormetoprim.

IV. EFFECTIVENESS

Five pivotal studies demonstrating the effectiveness of sulfadimethoxine and ormetoprim premix in chukar partridges were conducted under Public Master File (PMF) 5157. A notice of availability of this data in PMF 5157 was published in the FEDERAL REGISTER of July 19, 1996 (61 FR 37753).

V. ANIMAL SAFETY

A safety study conducted under PMF 5157 with 2.4X the recommended level of sulfadimethoxine and ormetoprim in complete feed for 28 days demonstrated no abnormalities in chukar partridges. A notice of availability of this data in PMF 5157 was published in the FEDERAL REGISTER of July 19, 1996 (61 FR 37753).

Although a study with 5X the recommended level of medicated feed was not conducted in chukars, a finding of no toxicity in chicks (pullets) fed a higher level of medicated feed (4X the recommended level) for 20 weeks was accepted as a basis for not requiring any additional safety studies in chukar partridges This data extrapolation is in accordance with 21 CFR 514.1(d)(2)(i).

VI. HUMAN FOOD SAFETY

The need for a tissue residue depletion study has been waived for the use 0.0125% of sulfadimethoxine and 0.0075% of ormetoprim in chukar partridges due to the extended period between treatment and release into commercial game preserves. The drug will be used to prevent coccidiosis, which is a disease of young birds (up to 8 weeks of age), and the birds will not be released into game preserves until at least 18 weeks of age. Therefore, the need for a tissue residue study is waived (61 FR 37753, July 19, 1996).

Tolerances of 0.1 ppm are established for residues of sulfadimethoxine and ormetoprim in edible tissues of chukar partridges.

VII. AGENCY CONCLUSIONS

The data submitted in support of this supplemental NADA comply with the requirements of Section 512 of the Federal Food, Drug, and Cosmetic Act and 21 CFR 514.1 of the implementing regulations. The data demonstrate that ROFENAID[®] 40 Type A medicated article (sulfadimethoxine and ormetoprim medicated feed), when used under labeled conditions of use is safe and effective for the prevention of coccidiosis caused by *Eimeria kofoidi* and *E. legionensis* in chukar partridges.

In accordance with 21 CFR 514.106(b)(2)(vii), this is a Category II supplement. This supplement provides for the use of sulfadimethoxine and ormetoprim medicated feed in chukar partridges, a new animal species. The approval of this change is not expected to have any adverse effect on the safety and effectiveness of this new animal drug. Accordingly, this approval did not require a reevaluation of the safety and effectiveness data in the parent application.

The use of the drug in chukar partridges has an inherent withdrawal period since birds are treated at a young age and subsequently held to maturity prior to release into game preserves. Therefore, the Center for Veterinary Medicine has waived the requirements for conducting a tissue residue depletion study. Tolerances of 0.1 ppm are established for residues of sulfadimethoxine and ormetoprim in edible tissues of chukar partridges.

The agency has determined that under 21 CFR 25.33(d)(4) this action is of a type that does not individually or cumulatively have a significant impact on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

Adequate directions for use of the product to treat chukar partridges has been written for the layperson, and the conditions for use prescribed on the labeling are likely to be followed in practice. Therefore, the Center for Veterinary Medicine (CVM) has concluded that this product shall continue to have over-the-counter marketing status.

VIII. APPROVED PRODUCT LABELING

A copy of the draft facsimile labeling is attached to this document.

- A. Rofenaid[®] 40 Type A Medicated Article Bag Label
- B. Blue Bird Label for Type C Medicated Feed